Mesoprogrestins (progesterone receptor modulations) as a component of compositions for hormone replacement therapy (HRT)
    1.
    发明授权
    Mesoprogrestins (progesterone receptor modulations) as a component of compositions for hormone replacement therapy (HRT) 有权
    作为激素替代疗法(HRT)组合物组分的Mesoprogrestins(孕酮受体调节)

    公开(公告)号:US07629334B1

    公开(公告)日:2009-12-08

    申请号:US10433984

    申请日:2000-08-31

    IPC分类号: A61K31/56 C07J1/00 C07J6/00

    CPC分类号: A61K31/56

    摘要: The use of mesoprogestins as pharmaceutical components for the manufacture of a medicament for hormone replacement therapy (HRT) and as components for the combined use together with an estrogen for the manufacture of a medicament for HRT as well as in respective HRT-methods and methods of treating hormone deficiency and hormone irregularity symptoms. Mesoprogestins are defined as compounds possessing both agonistic and antagonistic activities at the progesterone receptor (PR) in vivo. They stabilize the function of PR at an intermediate level of agonistic and antagonistic. Corresponding functional states cannot be achieved with progestins or antiprogestins. J867, J912, J956 and J1042 are the mesoprogestins preferred herein.

    摘要翻译: 使用中孕烯素作为药物组分用于制造用于激素替代疗法(HRT)的药物,以及作为与雌激素联合使用以用于制备用于HRT的药物的组合以及相应的HRT方法和方法 治疗激素缺乏和激素不规则症状。 中孕烯孕素被定义为在体内孕酮受体(PR)具有激动作用和拮抗活性的化合物。 他们将PR的功能稳定在激进和对抗的中间水平。 孕激素或抗孕激素不能达到相应的功能状态。 J867,J912,J956和J1042是本文优选的中孕酮。

    Mesoprogestins (progesterone receptor modulators) for the treatment and prevention of benign hormone dependent gynecological disorders
    2.
    发明授权
    Mesoprogestins (progesterone receptor modulators) for the treatment and prevention of benign hormone dependent gynecological disorders 有权
    美孕激素(孕激素受体调节剂)用于治疗和预防良性激素依赖性妇科疾病

    公开(公告)号:US08193252B1

    公开(公告)日:2012-06-05

    申请号:US10450029

    申请日:2000-08-31

    IPC分类号: A61K31/56

    摘要: This present invention disclosed the use of mesoprogestins, a new class of progesterone receptor modulators (PRMs), for the treatment and prevention of benign hormone dependent gynecological disorders: a) for the treatment of gynecological disorder such as endometriosis, uterine fibroids, postoperative peritoneal adhesions, dysfunctional bleeding (metrorrhagia, menorrhagia) and dysmenorrhea; b) for the prevention of gynecological disorders such as postoperative, peritoneal adhesions, dysfunctional uterine bleeding (metrorrhagia, menorrhagia) and dysmenorrhea; and c) a method of treatment and prevention of the above mentioned disorders in a female, preferably in a human female, in need of treatment or prevention of one or more of these disorders, with an effective amount of a mesoprogestin. Mesoprogestins are defined as compounds possessing both agonistic and antagonistic activities at the progesterone receptor (PR) in vivo. They stabilize the function of PR at an intermediate level of agonistic and antagonistic. Corresponding functional states cannot be achieved with progestins or antiprogestins. The daily dose of mesoprogestin is 0.5 to 100 mg, preferably 5.0 to 50 mg and most preferably 10 to 25 mg. J867, J912, J956 and J1042 are the mesoprogestins preferred according to the invention.

    摘要翻译: 本发明公开了用于治疗和预防良性激素依赖性妇科疾病的新型孕激素受体调节剂(PRM)的使用:a)用于治疗妇科疾病如子宫内膜异位症,子宫肌瘤,术后腹膜粘连 功能障碍性出血(metrorrhagia,月经过多)和痛经; b)用于预防妇科疾病如术后,腹膜粘连,功能障碍性子宫出血(metrorrhagia,月经过多)和痛经; 和c)有效量的中孕酮治疗和预防女性,优选在人类女性中需要治疗或预防这些疾病中的一种或多种的上述病症的方法。 中孕烯孕素被定义为在体内孕酮受体(PR)具有激动作用和拮抗活性的化合物。 他们将PR的功能稳定在激进和对抗的中间水平。 孕激素或抗孕激素不能达到相应的功能状态。 中孕酮的日剂量为0.5〜100mg,优选为5.0〜50mg,最优选为10〜25mg。 J867,J912,J956和J1042是根据本发明优选的中孕妇。